The Extension study : Using TOfogliflozin for Possible better Intervention against Atherosclerosis for Type 2 Diabetes Patients

The Extension study : Using TOfogliflozin for Possible better Intervention against Atherosclerosis for Type 2 Diabetes Patients - The Extension study : Using TOfogliflozin for Possible better Intervention against Atherosclerosis for Type 2 Diabetes Patients (UTOPIA Ex study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032601

Enrollment

340

Registered

2018-05-15

Start date

2018-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who had participated in the main study (UTOPIA study), and who agree to participate in this Extension study by providing their consent form

Exclusion criteria

Exclusion criteria: Those subjects who meet one of the following criteria are excluded: 1. subjects who disagree to participate in this Extension study 2. subjects determined ineligible by an investigator

Design outcomes

Primary

Measure	Time frame
Changes in the IMT value (mean and max IMT), measured by carotid arterial echography, from the start of main study (UTOPIA study) to the end of the observation period in this Extension study (208 week) *Particularly focusing on the change of the mean of right and left mean IMT during 208 weeks of the study period	—

Countries

Japan

Contacts

Public ContactNaoto Katakami

Osaka University Graduate School of Medicine Department of Metabolic Medicine

katakami@endmet.med.osaka-u.ac.jp06-6879-5111

Outcome results